ChemotherapyFDA-approvedFirst-line
FOLFIRINOX
How it works
FOLFIRINOX is a combination of four chemotherapy drugs: fluorouracil, leucovorin, irinotecan, and oxaliplatin. It works by interfering with DNA synthesis and cell division, causing cancer cells to die.
Cancer types
Pancreatic Cancer— All patients
Efficacy
Studies show that FOLFIRINOX can improve overall survival and response rates in patients with pancreatic cancer, with approximately 31% of patients achieving a complete response.
Side effects
Severe
This treatment carries a higher risk of serious side effects. Close medical monitoring is required throughout treatment.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| Testing Narmafotinib in Combination with FOLFIRINOX for Metastatic Pancreatic Cancer | Pancreatic Cancer | phase-1 | — | Source → |
| Combination Therapy for Untreated Metastatic Pancreatic Cancer | Pancreatic Cancer | phase-2 | — | Source → |
| Testing Pegcetacoplan with FOLFIRINOX for Advanced Pancreatic Cancer | Pancreatic Cancer | phase-1 | — | Source → |
| Testing a Combination Treatment for Metastatic Pancreatic Cancer | Pancreatic Cancer | phase-2 | — | Source → |
| FOLFIRINOX Chemotherapy for Advanced Pancreatic Cancer: Balancing Benefits and Harms | Pancreatic Cancer | phase-2 | Amongst the 66 patients who completed ≥ 4 cycles, 52 (79%) achieved disease control at FOLFIRINOX completion. | Source → |
| Germline Mutations Affect Pancreatic Cancer Treatment | Pancreatic Cancer | observational | Median progression-free survival was significantly longer in germline-positive patients (10.6 months) compared to germline-negative patients (5.3 months). | Source → |
| Combining Salmonella-IL2 with Chemotherapy for Stage IV Pancreatic Cancer | Pancreatic Cancer | phase-2 | Those patients who received more than five doses of Salmonella-IL2 with FOLFIRINOX had a median progression-free survival of 15 months and a median overall survival of 20.3 months. | Source → |
| Pancreatic Cancer Study Compares First-Line Treatments | Pancreatic Cancer | observational | Median OS was 14.5 months with FFX, 12.4 months with GN, 7.9 months with Gem, and 9.2 months with others. | Source → |
| Triweekly FOLFIRINOX Therapy for Advanced Pancreatic Cancer | Pancreatic Cancer | observational | The median overall survival was 14.2 months, and the median progression-free survival was 6.7 months. | Source → |
| Comparing Treatments for Early Recurring Pancreatic Cancer | Pancreatic Cancer | observational | The gemcitabine plus nab-paclitaxel group had a median overall survival of 14.5 months, compared to 11.1 months in the FOLFIRINOX group. | Source → |
| Combining CT Scans and Blood Tests to Predict Pancreatic Cancer Outcomes | Pancreatic Cancer | observational | Patients with progressive disease or increased CA 19-9 levels had a median overall survival of 14.3 months. | Source → |
| Pancreatic Cancer Study Finds New Way to Predict Treatment Outcomes | Pancreatic Cancer | observational | Patients with KRAS wild-type tumors had a median overall survival of 17.7 months, compared to 7.8 months for those with KRAS mutant tumors. | Source → |
| FOLFIRINOX Chemotherapy Toxicity Predictors in Pancreatic Cancer Patients | Pancreatic Cancer | observational | — | Source → |
| Induction Chemotherapy for Rectal Cancer with Synchronous Metastases | Colorectal Cancer | phase-3 | Triplet induction was associated with 80% of objective response and 92% of disease control. | Source → |
| Real-world Outcomes for Pancreatic Cancer Treatment | Pancreatic Cancer | review | In 9/17 clinical studies, median overall survival (mOS) ranged from 4.7 months to 11.4 months for FFX/mFFX, with the unweighted median of the estimates within this range being 9.2 months. | Source → |
| Pancreatic Cancer Treatment Comparison in Morocco | Pancreatic Cancer | observational | The median overall survival was 6 months for patients treated with Folfirinox versus 3 months for those treated with Gemcitabine. | Source → |
| Neoadjuvant Chemotherapy Response in Pancreatic Cancer | Pancreatic Cancer | observational | The 3-year overall survival rate was higher for biochemical responders (71.0%) than for radiology-only responders (53.6%) or non-responders (33.1%). | Source → |
| FOLFIRINOX Chemotherapy Affects Immune System in Pancreatic Cancer | Pancreatic Cancer | lab-study | — | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.